Azura Ophthalmics is utilizing a deep understanding of ocular surface diseases and drug development to deliver a new therapeutic class of ophthalmic keratolytics to treat underserved ophthalmic conditions.

Azura has a robust clinical-stage program focused on resolving the pathophysiology of meibomian gland dysfunction and contact lens discomfort.

It is Azura's belief that AZR-MD-001 can reverse the core pathophysiology of these conditions, alleviating their signs and symptoms.Additional areas of focus include the development of the company's novel new chemical entities, which target the pathophysiology of ocular surface diseases with a multi-modal mechanism of action.